Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems.

ABSTRACT:

Background

Recent work has developed solid drug nanoparticles (SDNs) of efavirenz that have been demonstrated, preclinically, improved oral bioavailability and the potential to enable up to a 50% dose reduction, and is currently being studied in a healthy volunteer clinical trial. Other SDN formulations are being studied for parenteral administration, either as intramuscular long-acting formulations, or for direct administration intravenously. The interaction of nanoparticles with the immunological and haematological systems can be a major barrier to successful translation but has been understudied for SDN formulations. Here we have conducted a preclinical evaluation of efavirenz SDN to assess their potential interaction with these systems. Platelet aggregation and activation, plas

SUBMITTER: Liptrott NJ 

PROVIDER: S-EPMC5853089 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature